Organogenesis Holdings Inc. (Nasdaq: ORGO) announced it plans to file a Biologics License Application (BLA) for its ReNu knee osteoarthritis treatment by the end of 2025 following a successful meeting with the US Food and Drug Administration.
"The successful completion of our planned Type-B meeting with the FDA gives us a clear path forward for our rolling BLA submission for ReNu," a company spokesperson said in a statement.
The regenerative medicine company confirmed the FDA agreed that its clinical development program is appropriate for a rolling submission. This process allows for the submission of completed portions of the application for FDA review, potentially expediting the approval timeline. ReNu is an amniotic fluid-derived injection intended to manage the pain associated with knee osteoarthritis, a market with millions of patients.
The successful FDA meeting is a significant milestone, substantially de-risking the regulatory pathway for what could become a major revenue generator for Organogenesis. Investors will now be watching for the initiation of the BLA submission before the end of 2025 and any subsequent updates on the review process from the FDA.
This article is for informational purposes only and does not constitute investment advice.
